Cancer stem cells in neuroblastoma therapy resistance
作者机构：Department of Radiation OncologyThe University of Oklahoma Health Sciences CenterOklahoma CityOK 73104USA Department of PathologyThe University of Oklahoma Health Sciences CenterOklahoma CityOK 73104USA Department of AnesthesiologyThe University of Oklahoma Health Sciences CenterOklahoma CityOK 73104USA Stephenson Cancer CenterOklahoma CityOK 73104USA
出 版 物：《Cancer Drug Resistance》 (癌症耐药（英文）)
年 卷 期：2019年第2卷第4期
页 面：948-967页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：The authors are supported by the research funding from the National Institutes of Health(NIH 1P20GM103639-01)from the COBRE Program of NIH OUHSC Department of Radiation Oncology Research Development Funds
主 题：Neuroblastoma therapy resistance cancer stem cells clonal selection drug resistance induced cancer stem cell
摘 要：Neuroblastoma(NB)is the most common cancer of infancy and accounts for nearly one tenth of pediatric cancer *** mortality rate has been attributed to the50%frequency of relapse despite intensive,multimodal clinical therapy in patients with progressive *** the disease’s heterogeneity and developed resistance,attaining a cure after relapse of progressive NB is highly challenging.A rapid decrease in the timeline between successive recurrences is likely due to the ongoing acquisition of genetic rearrangements in undifferentiated NB-cancer stem cells(CSCs).In this review,we present the current understanding of NB-CSCs,their intrinsic role in tumorigenesis,their function in disease progression,and their influence on acquired therapy resistance and tumor *** particular,this review focus on the intrinsic involvement of stem cells and signaling in the genesis of NB,the function of pre-existing CSCs in NB progression and therapy response,the formation and influence of induced CSCs(iCSCs)in drug resistance and tumor evolution,and the development of a CSC-targeted therapeutic approach.
维普期刊数据库